Constance A. Wilkinson, Member of the Firm, will Co-Chair this conference and join a panel discussion titled "Effectively Managing the Solicitation Process and Working With the Contracting Office."

Topics include:

  • Understanding the terms of the solicitation and the obligations imposed by FAR regulations incorporated into the agreement
  • Developing SOPs for dealing with the administrative requirements imposed by the FAR regulations
  • Identifying the correct forms that must be completed and completing them properly
  • Pre-award pricing disclosures
  • Negotiating who is a "comparable customer"
  • Gathering the information the manufacturer will need to provide during the course of the solicitation process
  • Determining when a contract needs to be modified what is expected when a modification is submitted?
  • Developing a roadmap for VA FSS pharmaceutical contract negotiations
  • How has the contracting offi ce evolved over the past year
  • What best practices would the contracting office like to see manufacturers employ?
  • What changes, if any, is the contracting office contemplating since the restructuring took place?

Benjamin S. Martin, Member of the Firm, will join a panel discussion titled "Managing the Implementation and Operational Challenges Resulting from Significant Changes to the 340B Program."

Topics include:

  • Purpose and function of the 340B program
  • Identifying 340B "covered entities" and "new" covered entities created under PPACA
  • Eligibility for new entities
  • Validating the eligibility of purchasers best practices for monitoring HRSA data
  • Distinguishing 340B sales from non-340B sales made to entities that fill both types of prescriptions
  • Managing the accrual uncertainty created by the expansion of the 340B program
  • Restrictions for participating covered entities
  • Understanding 340B pricing
  • Treatment of 340B sales in other federal drug pricing calculations
  • Adjusting PHS prices if and when prices are restated for Medicaid rebate purposes
  • Understanding how the new URA cap at 100% of AMP can still result in penny pricing and making system adjustments to capture this type of penny price
  • Recalculating the PHS price for "line extension" products
  • What obligations do manufacturers have to ensure that PHS pricing is available to covered entities?
  • Preventing double dipping by entities that participate in both 340B and GPO contracts
  • Update on the proposed rule for auditing processes and dispute resolution  

For more information, visit the American Conference Institute website.

Event Detail

Jump to Page

Privacy Preference Center

When you visit any website, it may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences or your device and is mostly used to make the site work as you expect it to. The information does not usually directly identify you, but it can give you a more personalized web experience. Because we respect your right to privacy, you can choose not to allow some types of cookies. Click on the different category headings to find out more and change our default settings. However, blocking some types of cookies may impact your experience of the site and the services we are able to offer.

Strictly Necessary Cookies

These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.

Performance Cookies

These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.